Esperion Therapeutics Inc (NAS:ESPR)
$ 2.12 0.12 (6%) Market Cap: 415.99 Mil Enterprise Value: 472.28 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 53/100

Q1 2020 Esperion Therapeutics Inc Earnings Call Transcript

May 06, 2020 / 08:30PM GMT
Release Date Price: $40.6 (+0.15%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome. (Operator Instructions) Please be advised that today's conference call may be recorded.

I would now like to hand the conference call over to one of your speakers today, Mr. Alex Schwartz, Head of Investor Relations. Please go ahead, sir.

Alexander Duke Schwartz
Esperion Therapeutics, Inc. - Senior Director of IR

Thank you, Felicia. Good afternoon, ladies and gentlemen, and welcome to Esperion's first quarter financial results and company update conference call and webcast. I'm Alex Schwartz, Head of Investor Relations at Esperion. (Operator Instructions)

Joining me for today's call are Tim Mayleben, President and Chief Executive Officer; Mark Glickman, Chief Commercial Officer; and Rick Bartram, Chief Financial Officer.

I'd like to remind callers that the information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements. Actual

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot